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Abstract
Trypanosoma cruzi (T. cruzi) infection produces an intense inflammatory response which is critical for the control of the
evolution of Chagas’ disease. Interleukin (IL)-10 is one of the most important anti-inflammatory cytokines identified as
modulator of the inflammatory reaction. This work shows that exogenous addition of IL-10 inhibited ERK1/2 and NF-kB
activation and reduced inducible nitric oxide synthase (NOS2), metalloprotease (MMP) -9 and MMP-2 expression and
activities, as well as tumour necrosis factor (TNF)-a and interleukin (IL)-6 expression, in T. cruzi-infected cardiomyocytes. We
found that T. cruzi and IL-10 promote STAT3 phosphorylation and up-regulate the expression of suppressor of cytokine
signalling (SOCS)-3 thereby preventing NF-kB nuclear translocation and ERK1/2 phosphorylation. Specific knockdown of
SOCS-3 by small interfering RNA (siRNA) impeded the IL-10-mediated inhibition of NF-kB and ERK1/2 activation. As a result,
the levels of studied pro-inflammatory mediators were restored in infected cardiomyocytes. Our study reports the first
evidence that T. cruzi up- regulates SOCS-3 expression and highlights the relevance of IL-10 in the modulation of pro-
inflammatory response of cardiomyocytes in Chagas’ disease.
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Introduction
Chagas’ disease is a chronic and systemic infection caused by
the protozoan parasite Trypanosoma cruzi. The acute phase of
infection is characterized by the presence of parasites in the host
bloodstream and diverse tissues. However, the heart is one of the
principal targets of this disease, causing serious cardiac alterations
in the acute and chronic phases. Our group and others have
previously described that during the acute phase of the disease,
there is induction and high-level expression of pro-inflammatory
cytokines as well as of inducible nitric oxide synthase (NOS2) [1–
4], prostaglandins [5,6] and chemokines [7]. A number of cardiac
pathophysiological conditions, including myocardial infarction
and ischemia-reperfusion injury leading to heart failure, are
associated with activation of inflammatory mediators in the heart
[3,4]. Expression of pro-inflammatory cytokines, such as tumor
necrosis factor-a (TNF-a), interleukin-1 (IL-1) and interleukin-6
(IL-6) and anti-inflammatory cytokine IL-10, mediate homeostasis
within the heart in response to injury. However, a sustained
expression of pro-inflammatory mediators at sufficiently high
concentrations could lead to an adverse outcome, including heart
failure [8–10]. The inflammatory response is a key component of
host defense, but excessive inflammation such as that occurring in
several inflammatory diseases can be deleterious or even fatal.
Therefore, inflammation must be tightly regulated. Interleukin-10
(IL-10) is a key inhibitor of many aspects of the inflammatory
response. This cytokine is a potent anti-inflammatory cytokine, a
strong deactivator of monocytes and suppressor of various pro-
inflammatory mediators [11,12]. However, the therapeutic effects
of systemic IL-10 on inflammation-mediated cardiac dysfunction
and remodeling, as well as the molecular signaling pathways that
explain these effects, remain to be elucidated. Engagement of the
IL-10 receptor has been shown to involve the JAK-STAT
signaling pathway inducing the activation of STAT1, STAT3,
and, in some cells, STAT5 [13]. STAT3 can be activated not only
by IL-10 signaling, but also by many other cytokines like IL-6,
transcription factors and oncogenic proteins [14–16]. In response
to cytokine signaling, STAT3 activates certain genes whose
products were identified in the mid-1990s as suppressors of
cytokine signaling (SOCS) [17]. Some authors suggest that, among
them, SOCS-1 and SOCS-3 are induced only by IL-10-mediated
signaling [18,19]. It has been described that SOCS-3 exerts its
anti-inflammatory effects by inhibition of the activation of the NF-
kB pathway. In fact, Nair et al. [20] demonstrated that the PPE18
protein of Mycobacterium tuberculosis inhibits LPS-induced IL-12 and
TNF-a production by blocking nuclear translocation of p50, p65
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NF-kB, and c-rel transcription factors in macrophages. These
authors found that PPE18 up-regulates the expression as well as
tyrosine phosphorylation of SOCS-3, and that phosphorylated
SOCS-3 physically interacts with the IkBa–NFkB/rel complex,
inhibiting phosphorylation of IkBa. It has been described that
SOCS-2 is expressed during T. cruzi infection and it is postulated
that it may therefore participate in the pathogenesis of Chagas’
disease by modulating heart damage [21]. However, the
significance of SOCS-3 in the modulation of inflammatory
response in T. cruzi infection has not been studied.
The aim of this work was to analyse whether the addition of
exogenous IL-10 modulates inflammatory mediators produced by
T. cruzi-infected cardiomyocytes and the molecular events leading
to such regulation. Our results show that IL-10 leads to STAT3
activation and up-regulation of SOCS-3. Moreover, specific
SOCS-3 knock-down by SOCS-3-siRNA revealed that IL-10
anti-inflammatory effect involves inhibition of NF-kB and ERK
signaling with the consequent downregulation of cytokines, NOS2
and matrix metalloproteinases (MMPs) by means of STAT3/
SOCS-3 activation pathway.
Materials and Methods
Mice and Infection
Twenty one days-old male CF1 mice used in this study were
infected by intraperitoneal route with 16105 bloodstream
trypomastigotes of the lethal pantropic/reticulotropic RA strain
of Trypanosoma cruzi, as previously described [22]. All animal
experiments were approved by the Institutional Committee for the
Care and Use of Laboratory Animals (SICUAL, University of
Buenos Aires School of Medicine). The protocols are in
accordance with guidelines of the Argentinean National Admin-
istration of Medicines, Food and Medical Technology (ANMAT),
Argentinean National Service of Sanity and Agrifoods Quality
(SENASA) and also based on the US NIH Guide for the Care and
Use of Laboratory Animals.
Neonatal Mouse Primary Cardiomyocytes Culture
One- to three-day old neonatal CF-1 mice were euthanized by
cervical dislocation. The hearts were aseptically removed and kept
in Hanks’ balanced salt solution without Ca2+ and Mg2+ (HBSS 1)
(in g/1:0.4 KCl, 0.06 KH2PO4, 8.0 NaCl, and 0.05 Na2HPO4,
pH 7.4) on ice. The tissues were washed three times and minced
into small fragments. The cells were dissociated with trypsin
(Sigma-Aldrich Co., St. Louis, USA) (0.25% wt/vol in HBSS 1) at
37uC. The released cells obtained after the first digestion were
discarded, whereas the cells from subsequent digestions were
added to an equal volume of cold HBSS 1 with Ca2+ and Mg2+:
HBSS 2 (in g/l: HBSS 1 plus 0.14 CaCl2, 0.047 MgCl2,
0.049 MgSO4, 0.35 NaHCO3, and 1.0 D-glucose, pH 7.4) until
all cardiac cells were isolated [23]. The resulting cell suspension
was centrifuged at 200 g for 8 min, and the cells were resuspended
in DMEM: M-199 medium (GibcoTM, Grand Island, N.Y., USA)
(4:1, vo/vol) supplemented with 10% Foetal Calf Serum (FCS)
(PAA Laboratories GmbH, Haidmannweg, Austria) and antibiot-
ics (50 mg/ml of penicillin, streptomycin, and gentamicin). To
exclude non-muscle cells, the isolated cells were first plated in
tissue culture dishes at 37uC for 2 h under a water-saturated
atmosphere of 5% CO2. The non-adherent cells were then
collected and plated at a density of 1.06105 cells cm2 in 10% FCS-
DMEM: M-199 and antibiotics. More than 90% of cells were
cardiomyocytes as detected by immunostaining with antibody to
a-actinin (Sigma-Aldrich Co., St. Louis, USA). After 48 h, the
culture medium was changed to 1% FCS-DMEM: M-199 4:1
(vol/vol) with or without antibiotics. The cells were infected for the
indicated periods of time with Trypanosoma cruzi RA strain, treated
with IL-10 (BD PharmigenTM CA, USA), STAT3-specific
Inhibitor V stattic [24] (Santa Cruz Biotechnology Inc., CA,
USA) or transfected with SOCS-3-siRNA (Santa Cruz Biotech-
nology Inc., CA, USA). The solvent for IL-10 was a sterile aqueous
solution containing 2.5 mg/ml BSA, and the solvent for stattic was
DMSO. SOCS-3 siRNA was resuspended in RNAse-free water.
After different treatments cell viability was examined by Trypan
blue dye exclusion test.
Infection of Myocardial Cells by Trypanosoma cruzi
Bloodstream trypomastigotes used to infect culture cardiomy-
ocytes were obtained by cardiac puncture, from euthanised 21
days-old male CF-1 mice infected 7 days before with trypomas-
tigotes of the RA strain of T. cruzi. Briefly, blood diluted 1:2 in
DMEM was centrifuged at 400 g at room temperature and then
left at 37uC for 1 h in a water bath. Cardiomyocytes were infected
at a 5:1 parasite:cell ratio in six- (26106 cell/well) or 24- (56105
cell/well) well polystyrene plates (containing round glass cover-
slips). After 3 h, the infected cultures were washed with 1% FCS-
DMEM:M-199 fresh medium five times to remove free parasites
and then the cells were cultured for different periods (24, 48 or
72 h) under the same conditions.
NO Measurement
To determine the amount of NO released into the medium,
nitrate was reduced to nitrite, and this was measured spectropho-
tometrically by the Griess reaction, as previously described [25].
The absorbance at 540 nm was compared with a standard curve
of NaNO2. In situ NO synthesis was performed in cardiomyocytes
loaded with 4-Amino-5-Methylamino-29,79-Difluorofluorescein
Diacetate (DAF-FM), following the controls and recommendations
of the supplier (Molecular Probes,Eugene, OR, USA). DAF-DM is
a non-fluorescent compound that reacts with NO to form
fluorescent benzotrizole with excitation/emission at 495/515 nm.
Quantitative Real-time RT-PCR (Q-RT-PCR)
Total RNA was extracted from frozen cells using Trizol reagent
(Life Technologies, Inc., CA, USA). Total RNA was reverse
transcribed using Expand Reverse Transcriptase (Promega Cor-
poration, Wisconsin, USA). Q-RT-PCR was performed using
SyBr Green PCR kit (PE Applied Biosystems Inc., CA, USA) in an
Applied Biosystems 7500 sequence detector. Primer sequences
were: MMP-2 forward: 59-CGGAGATCTGCAAACAGGACA-
39, reverse: 59-CGCCAAATAAACCGGTCCTT-3; MMP-9 for-
ward: 59-CAGACCAAGGGTACAGCCTGTT-39, reverse: 59-
AGTGCATGGCCGAACTC-39; TNF-a forward: 59-ATGAG-
CACAGAAAGCATGATC-39, reverse: 59-TACAGGCTTGT-
CACTCGAATT-39; IL-6 forward: 59-TGATGCACTTGCA-
GAAAACAA-39, reverse: 59-
GGTCTTGGTCCTTAGCCACTC-39. SOCS-3 forward: 59-
CCTTTGACAAGCGGACTCTC-39, reverse: 59-GCCAGCA-
TAAAAACCCTTCA-39. All samples were analysed in the same
run with 18S rRNA amplification for normalization: forward: 59-
AACACGGGAAACCTCACCC-39, and reverse: 59-CCAC-
CAACTAAGAACGGCCA-39. PCR parameters were 50uC for
2 min, 94uC for 2 min, and 40 cycles of 94uC for 30 s, 60uC (for
MMP-9, MMP-2, TNF-a, SOCS-3 and 18S) or 54uC (for IL-6) for
1 min. Quantification was calculated using the comparative
threshold cycle (Ct) method and efficiency of the RT reaction
(relative quantity, 22DDCt). The replicates were then averaged and
fold induction was determined, considering the value at zero time
as 1 [23].
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Small Interfering RNA (siRNA)
Cardiomyocytes were cultured up to 30–50% of confluence in
DMEM: M-199 medium containing 5% FCS without antibiotics
for 24 h. After that, cells were transfected with SOCS-3 siRNA
that targets SOCS-3 mRNA, following the manufacturer’s
instructions (Santa Cruz Biotechnology Inc., CA, USA). Trans-
fections were performed with Oligofectamine (Life Technologies,
Inc., CA, USA) as specified by the manufacturer. Assays for gene
activity were performed at 24 and 72 h post transfection. The
impact of SOCS-3-siRNA interference on SOCS-3 mRNA was
evaluated by Q-RT-PCR.
Measurement of IL-10 Production
IL-10 concentrations were measured in cell culture supernatants
by ELISA. The procedures for ELISA kits (BD Biosciences
OptEIA) were performed according to the manufacturer’s
instructions. The reaction was detected by peroxidase-conjugated
Streptavidin followed by a substrate mixture that contained
hydrogen peroxide as a substrate and ABTS (Sigma Aldrich Co.,
St. Louis, USA) as a chromogen. The absorbance measured at
405 nm was compared with IL-10 standard curve.
Preparation of Cytosolic, Nuclear and Total Protein
Extracts and Western Blot
Cultured cells were washed with PBS and scraped off the dishes
with 100 ml of buffer A (10 mmol/l HEPES; pH 7.9, 1 mmol/l
EDTA, 1 mmol/l EGTA, 10 mmol/l KCl, 1 mmol/l DTT,
0.5 mmol/l phenylmethyl sulfonyl fluoride, 40 mg/ml leupeptin,
2 mg/ml tosyl-lysyl-chloromethane, 5 mmol/l NaF, 1 mmol/l
NaVO4, 10 mmol/l Na2MoO4), and NP-40 was added to reach
0.5% (vol/vol). After 15 min at 4uC, the tubes were gently
vortexed for 10 s, and cytosolic extracts were collected by
centrifugation at 13,000 g for 30 s. The supernatants were stored
at 220uC (cytosolic extracts). Nuclear proteins were obtained by
centrifugation at 13,000 g for 5 min, and a liquots of the
supernatant (nuclear extracts) were stored at 280uC.
Total protein extracts were obtained after washing cells with
PBS and adding OGP (Sigma-Aldrich Co., St. Louis, USA).) lysis
buffer (90 ml/dish). Then, the dishes were kept on ice for 30 min
with swirling and the scrapped cells were centrifuged at 7,000 g at
4uC for 10 min. The supernatant was transferred to a clean tube
and stored at 220uC. Protein concentration was determined by
Bradford method using Bio-Rad Protein Assay (BIO-RAD CA.,
USA) reagent and bovine serum albumin (BSA) (Sigma-Aldrich
Co., St. Louis, USA) as pattern protein [25].
For Western blot analysis, cytosolic or total proteins were boiled
in Laemmli sample buffer, and equal amounts of protein (40–
50 mg) were separated by 10–12% SDS-PAGE. The gels were
blotted onto a Hybond-P membrane (GE Health-care, Madrid,
Spain) and incubated with the following antibodies (Abs): anti-
NOS2, anti- IkB-a, anti-p65, anti-Sp1 (Santa Cruz Biotechnology,
CA, USA), anti-P-ERK1/2, anti-P-Tyr705-STAT3 (Cell Signal-
ling Technology Inc., MA, USA) and anti-a-actin (Sigma-Aldrich
Co., St. Louis, USA). The blots were revealed by enhanced
chemoluminiscence (ECL) in an Image Quant 300 cabinet (GE
Healthcare Biosciences, PA, USA) following the manufacturer
instructions. Band intensity was analysed using NIH-image J
program [23].
Peritoneal Macrophages Isolation and Activation
Macrophages were obtained by washing the peritoneal cavity of
BALB/c mice with 5 ml of Dulbecco’s Modified Eagle Medium
(D-MEM; Invitrogen Life Technologies, Grand Island, NY)
supplemented with 10% of heat-inactivated FCS. Cells were left
to adhere to plastic for 2 h at 37uC. After washing twice with
phosphate buffer saline (PBS), adherent cells were scraped and
suspended in culture medium. Cell viability (.95%) was assessed
by Trypan blue dye exclusion test. For activation macrophages
were treated with 1 mg/ml of LPS from Eschericchia coli (Sigma–
Aldrich, St. Louis, MO) for 24 h.
Zymography
MMP activity in cell culture supernatants was measured using
gelatin in-gel zymography. Culture media were subjected to a
7.5% SDS-PAGE, in which 1 mg/ml gelatin (type A from
porcine skin) had been incorporated. Following electrophoresis,
gels were washed in 30% Triton X-100 for 60 min to remove
SDS. Then, the gels were incubated in 50 mM Tris buffer
pH 7.4, containing 0.15 mM NaCl and 30 mM CaCl2, for 36 h
at 37uC. Gels were stained with Coomassie blue and then
destained with 10% acetic acid and 30% methanol in water.
The areas of proteolytic activity appeared as negative-stained
bands in the dark background. The identities of MMPs were
based on their molecular weights and a positive internal control
(activated peritoneal macrophages) was run in each gel to allow
the standardization of the results obtained in the different
zymograms. Fifty mg total supernatant protein (Bradford) was
loaded onto each lane. A pre-stained molecular weight marker
(Bio-Rad, USA) was used to assess the MW of the bands. After
staining with Coomassie blue and destaining, clear and digested
regions representing MMPs activity were quantified by densi-
tometry using NIH-image J program.
Immunofluorescence and Digital Image Analysis
Parasite staining and digital imaging were performed as
previously described by Hovsepian et al., with minor modifica-
tions [3]. Briefly, myocardial cells grown on round glass
coverslips were blocked with 3% normal goat serum in PBS.
The percentage of infected cells and the number of amastigotes
per cell were determined by analyzing the presence of
intracellular amastigotes by immunofluorescence. For this
purpose, a rabbit polyclonal IgG directed to T. cruzi and a
FITC-labelled goat anti-rabbit IgG (Sigma–Aldrich) were used
at 1:200 dilutions (determined by titration). Myocardial cells
nuclei were stained with DAPI (300 nM in PBS). At least 30
random microscopic fields (400X) and 1000 cells per culture
were acquired using a Spot RT digital camera attached to an
Eclipse 600 fluorescence microscope (Nikon Inc., USA). Cell
quantification was performed with the ImageJ open source
software developed at the NIH, USA.
Statistical Analysis
Results are the average6SD of at least three separate
experiments. P values were determined using Student’s t-test
or Tukey test for nonparametric values. P,0.05 was considered
to be statistically significant. For percentages of infected cells
and number of amastigotes per cell, the differences were
established for a significance level of a= 0.05 by one-way
ANOVA and the Tukey post-test. NO levels were quantified by
integrating the area of fluorescence, under the assumption that
pixel density is directly proportional to NO production. The
differences were established for a significance level of a= 0.05
by one-way ANOVA and Bonferroni test for multiple compar-
ison. Statistical analyses were performed using GraphPad Prism
4.0 program.
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Results
Exogenous IL-10 Attenuates NF-kB and ERK Activity in T.
cruzi-infected Cardiomyocytes
Recombinant mouse IL-10 cytokine inhibited T. cruzi-induced
pro-inflammatory mediators like NO in a concentration-depen-
dent manner in infected cardiomyocytes (Figure 1A). IL-10 at a
concentration of 20 ng/ml significantly inhibited NO production.
Therefore, 20 ng/ml was used for all our subsequent experiments.
The transcription factor NF-kB and the ERK/MAPK signaling
pathways are known to participate in the induction of proin-
flammatory genes. For that reason, we evaluated if their activities
were modified upon IL-10 addition to infected cardiomyocytes.
Since IL-10 was found to inhibit NO in T. cruzi-infected
cardiomyocytes (Figure 1A), we next examined ERK/MAPK
activation and the nuclear levels of p65-NF-kB protein in these
cells by Western blotting, using specific antibodies against these
transcription factors. Cultured cardiomyocytes were incubated
with IL-10 (20 ng/ml) and, after T. cruzi infection, ERK1/2
phosphorylation was assessed. IL-10 significantly inhibited ERK1/
2 phosphorylation (Figure 1B). Nuclear levels of p65 were also
decreased in infected and IL-10-treated cardiomyocytes as
compared with the untreated infected cells (Figure 1C). It is
known that the NF-kB inhibitor IkBa interacts and sequesters p65
among other proteins of the NF-kB complex in the cytoplasm,
preventing its nuclear translocation and the transcription of the
target genes. Therefore, we next determined whether IL-10
modifies IkBa cytoplasmic levels in infected cardiomyocytes.
Figure 1D shows that IkBa remained in the cytoplasm of IL-10-
treated infected cardiomyocytes similarly to the control cells,
indicating inhibition of NF-kB activity.
T. cruzi and Exogenous IL-10 Promote STAT3 Activation
and SOCS-3 Expression
Taking into consideration that cytokines can activate STAT
proteins, we sought to determine whether STAT3 transcription
factor had a role in the signaling pathway that is initiated by T.
cruzi infection and by a pleiotropic cytokine like IL-10. However,
Figure 1. IL-10 inhibits cardiomyocytes inflammatory response induced by T. cruzi infection. (A) Cardiomyocytes were pre-treated with
IL-10 (10 ng/ml or 20 ng/ml) for 15 min before T. cruzi infection (with parasite:cell ratio 5:1) and NO levels were quantified by Griess reaction in the
culture media after 48 h (n = 3). (B) Neonatal cardiac cells were infected for 10 and 20 min or pre-treated for 15 min with 20 ng/ml of IL-10 and
cytosolic extracts were prepared. The levels of P-ERK1/2-MAPK were determined by Wb with specific antibodies. (C) Cells were pre-treated with IL-
10 in the same conditions as in B and infected with T. cruzi during 30 or 120 minutes for p65 nuclear detection or (D) pre-treated with IL-10 and
infected for 15 or 30 min for cytosolic detection of IkB-a. For NO measurement, results are expressed as mean6SD (n = 4). For B, C and D results show
a representative experiment of three performed and protein levels were normalized against a-actin (B and D) and Sp1 (C). Mean6SD (n = 3). **p,0.01
vs. control cells; #p,0.05 vs. T. cruzi infected cells.
doi:10.1371/journal.pone.0079445.g001
T. cruzi: IL-10/SOCS-3 Pathway in Cardiac Cells
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e79445
endogenous IL-10 was undetectable at the protein (ELISA) and
mRNA (Q-RT-PCR) levels. Therefore, we tested the kinetics of
IL-6 at the transcription level using Q-RT-PCR to test whether
this cytokine was responsible for STAT3 activation. We detected
IL-6 mRNA at 4 h after T. cruzi infection (Figure 2A). STAT3
activation was evaluated by the detection of the phosphorylated
form of STAT3 by Western blot. These results indicate that both
the infection with T. cruzi and IL-10 treatment are capable of
activating STAT3 as early as 30 min after infection, since in both
cases we detected the P-STAT3 form (Figure 2B). It has been
suggested that, in response to cytokine signaling or to microor-
ganisms, STAT3 activates SOCS-3 proteins involving the latter in
the attenuation of pro-inflammatory signaling [17,20]. Thereby,
we speculated that SOCS-3 might have a role in the IL-10-
mediated down-regulation of the pro-inflammatory response.
Interestingly, an increase in SOCS-3 mRNA level was observed
at 1 h or 2 h with either T. cruzi or IL-10, being the latter
significantly greater (Figure 2C). We also determined a direct
correlation between STAT3 activation and SOCS-3 expression,
since in the presence of stattic, an inhibitor of STAT3, SOCS-3
expression was prevented both in infected cells and in those
treated with IL-10 (Figure 2D).
IL-10 Attenuates NF-kB and ERK Activity through SOCS-3
Given that IL-10 increases SOCS-3 levels and inhibits both
T. cruzi-induced NF-kB and ERK activities, we postulated that
SOCS-3 is the intermediary through which IL-10 acts in this
experimental model. To corroborate this hypothesis, we silenced
SOCS-3 expression by using SOCS-3-specific siRNA and
evaluated the role of IL-10 on NF-kB and ERK activities in
T. cruzi-infected cardiomyocytes. First, we performed Q-RT-
PCR assays 72 h after transfection with SOCS-3-siRNA to
evaluate the silencing efficiency. Figure 3A shows that the
expression of SOCS-3 evidenced after T. cruzi infection and IL-
10 treatment was silenced in transfected cells. In order to
evaluate ERK1/2 and NF-kB activation pathways, cells were
transfected with SOCS-3-siRNA, infected and pretreated with
IL-10. Western blotting showed that SOCS-3 silencing prevent-
ed the inhibitory effect of IL-10 on the phosphorylation of
ERK1/2 (Figure 3B). Cells transfected with SOCS-3-siRNA and
treated with IL-10 showed IkB-a levels similar to those
observed after infection, indicating that SOCS-3 is required
for IL-10 inhibition of NF-kB (Figure 3C).
Figure 2. T. cruzi and IL-10 promote STAT3 activation and SOCS-3 expression. (A) Kinetics of IL-6 transcription after T. cruzi infection of
cardiomyocytes. Cells were infected with T. cruzi trypomastigotes and at different time points mRNA for IL-6 was assessed using Q-RT-PCR. (B) Cells
were infected or treated with IL-10 (20 ng/ml) or pre-treated with IL-10 and infected for 30 min and STAT3 activation was analysed by Wb. (C)
Neonatal cardiomyocytes were infected or treated with IL-10 (20 ng/ml) for 1 or 2 h, and SOCS-3 mRNA levels were analysed by Q-RT-PCR. (D) Cells
were pre-incubated with STAT3 inhibitor, stattic (10 mM), for 30 min before 1 h of T. cruzi infection or IL-10 treatment and SOCS-3 mRNA levels were
analysed by Q-RT-PCR. For A, C and D, results were normalized against 18S and represent the mean6SD of three independent experiments. For B,
results show the mean6SD (n = 3) and protein levels were normalized against a-actin. **p,0.01 vs. control cells; *p,0.05 vs. control cells;ˆp,0.01 vs.
T. cruzi infected cells; ep,0.01 vs. IL-10 treated cells.
doi:10.1371/journal.pone.0079445.g002
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IL-10 Inhibits Inflammatory Mediators in T. cruzi-infected
Cardiomyocytes
Since IL-10 is involved in the control of the inflammatory
response, we decided to study the effects of exogenous IL-10
addition on inflammatory mediators. Previous results have shown
that cardiomyocytes are able to produce cytokine and NOS2
expression after T. cruzi infection [3]. When cardiomyocytes were
pre-incubated with IL-10 (20 ng/ml), Q-RT-PCR results showed
a significant decrease in IL-6 and TNF-a mRNA levels after 4 h of
infection (Figure 4A). Western blotting assays also revealed that
IL-10 is capable of inhibiting NOS2 protein expression in T. cruzi-
infected cells (Figure 4B). In addition, we evaluated the in situ
synthesis of NO by using 4-amino-5-methylamino-29,79-difluoro-
fluorescein (DAF-FM), a highly sensitive indicator of the presence
of NO. This reagent is virtually non-fluorescent until it reacts with
NO, forming the fluorescent benzotriazole. Cardiomyocytes
infected with T. cruzi for 48 h showed intense fluorescence,
whereas those treated with IL-10 showed no fluorescent label
(Figure 4C), indicating a clear inhibition of NO production.
Based on these results, we decided to investigate whether IL-10
also has some effect on MMPs expression induced in cardiomy-
ocytes by T. cruzi infection. For this purpose, we used Q-RT-PCR
to evaluate MMP-9 and MMP-2 expression in cardiomyocytes
infected and treated with IL-10. Figure 5A shows that IL-10
(20 ng/ml) inhibited the expression of both MMPs significantly
compared with enzyme levels induced after 48 h of infection with
T. cruzi. To evaluate whether the inhibition of mRNA expression
exerted by IL-10 correlated with the activity of these enzymes,
supernatants of cultured cardiomyocytes treated or not with IL-10
and infected for 72 h were tested by zymography. IL-10
significantly inhibited the gelatinolytic activity of proenzymes
MMP-9 and MMP-2 induced by infection with T. cruzi in
cardiomyocytes (Figure 5B).
SOCS-3 is Involved in the Anti-inflammatory Effects
Exerted by IL-10 in T. cruzi-infected Cardiomyocytes
Given that IL-10 enhances the expression of SOCS-3 and its
silencing prevents ERK/MAPK and NF-kB inhibition of its
activation, we sought to determine whether SOCS-3 also
participates in the inhibition of inflammatory mediators in infected
cells pre-treated with IL-10. Therefore, cells were treated with IL-
10 and infected or transfected with SOCS-3-siRNA, and NO
production as well as NOS2, cytokines, MMP9 and MMP2
expression were evaluated. Figure 6A and 6B show that when
SOCS-3 was silenced in cardiomyocytes, IL-10 was unable to
exert its modulatory effects on NOS2 expression or NO
production. Similarly, in conditions of silencing of SOCS-3,
IL10 was uncapable to inhibit the expression of TNF-a and IL-6
(Figure 6C and 6D). This was also found regarding the expression
of MMP-9 and MMP-2, as shown in Figure 6E and 6F. No
significant differences were found in the pro-inflammatory
responses of infected cardiomyocytes, either silenced or not in
the absence of IL-10 treatment (Data not shown). These results
confirm that the STAT3/SOCS-3 pathway participates in the
regulatory effects of IL-10 on T. cruzi-infected cardiomyocytes.
SOCS-3 Silencing Reverts IL-10-induced Cardiomyocytes
Parasitism
In light of the effects of IL-10 on the pro-inflammatory response
of cardiomyocytes during T. cruzi infection and the reversion of
these effects by SOCS-3 silencing, we decided to determine the
effects of this cytokine and SOCS-3 silencing on the percentage of
infected cells and on the parasite load. Cells grown on glass
coverslips were infected, infected and treated with IL-10 or
silenced by siRNA and then infected and treated with IL-10. As
expected, due to the inhibition of the anti-parasitic effector
mechanisms exerted by IL-10, increased percentage of infected
cells and number of amastigotes/cell were observed in IL-10-
treated cardiomyocytes (Figure 7). Silencing of SOCS-3 with
siRNA reverted this effect. Silencing of SOCS-3 did not modify T.
cruzi parasitism in IL-10-untreated cells (data not shown).
Figure 3. SOCS-3 is involved in the inhibition of ERK1/2-MAPK
and NF-kB after IL-10 treatment of infected cardiomyocytes. (A)
Cells were transfected with SOCS-3 siRNA for 72 h, infected with T. cruzi
or treated with IL-10 for 1 h and SOCS-3 mRNA levels were analysed by
Q-RT-PCR. (B) Cells were infected with T. cruzi, pre-treated with IL-10 or
transfected with SOCS-3 siRNA for 72 h or pre-treated with IL-10 and
infected for 20 min. P-ERK1/2-MAPK levels were determined by Wb with
specific antibodies. (C) Cytosolic extracts from cardiomyocytes in the
same conditions as in B but infected for 30 min were analysed by Wb to
determine IkB-a expression. For A, results were normalized against 18S
and represent the mean6SD of three independent experiments. For B
and C, results show the mean6SD (n = 3) and protein levels were
normalized against a-actin. **p,0.01 vs. control cells;ˆp,0.01 vs. T. cruzi
infected cells; #p,0.05 vs. T. cruzi infected cells; ep,0.01 vs. IL-10
treated cells; Qp,0.05 vs. T. cruzi infected+IL-10 treated cells.
doi:10.1371/journal.pone.0079445.g003
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Discussion
In this study, we investigated the ability of IL-10 to inhibit NF-
kB and ERK/MAPK pathways and consequently the production
of pro-inflammatory mediators through the up-regulation of
SOCS-3 expression in T. cruzi-infected cardiomyocytes.
During the acute phase of T. cruzi infection, cardiomyocytes,
which produce cytokines such as IL-1b, IL-6 and TNF-a and
mediators like NO, play an important role in the development of
local inflammatory response [3]. In the early 1990s, it was
described that the production of TGF-b and IL-10 are key to the
inhibition of increased levels of IFN-c and their damaging effects
induced in response to T. cruzi infection both in vitro and in vivo
experimental models [26,27]. Later on, it was shown that IL-10
knockout mice are more susceptible to infection and have higher
mortality rates than wild-type mice [28,29]. Furthermore, it has
been reported that a deficiency in the regulatory mechanisms of
the inflammation in chagasic patients, either by lack of IL-10
production or excessive IFN-c, could contribute to the pathogen-
esis of the disease [30]. In this regard, it has been reported that
peripheral blood mononuclear cells isolated from patients in the
indeterminate phase of Chagas’ disease produce higher levels of
IL-10 than those isolated from patients with chronic cardiomyop-
athy [31,32].
Based on these records, we investigated the role of IL-10 in our
model of T. cruzi-infected cardiomyocytes with the lethal RA
strain. We assessed the endogenous synthesis of IL-10 in primary
cultures of infected cardiomyocytes, but could neither detect its
expression by Q-RT-PCR assays nor in the supernatants using a
commercial ELISA kit (data not shown). These results are
consistent with those of Ponce NE. et al. [16], who described that
isolated cardiomyocytes infected with T. cruzi do not produce
detectable amounts of IL-10. However, in in vivo models of
infection with T. cruzi, the cardiac expression of IL-10 has been
associated with the extent of the inflammatory infiltrates present in
the heart [33,34]. In a previous work, we detected significant levels
of IL-10 in the sera from mice infected with the RA and K98
strains of T. cruzi with different lethality [4]. These antecedents led
us to evaluate the effects of the exogenous addition of IL-10 in
cultures of infected cardiomyocytes. The present results show
inhibition of NOS2 expression, by Western blotting and activity,
using Griess assays, as well as using 4-amino-5-methylamino-2
9,79-difluorofluorescein (DAF-FM), an indicator of in situ NO
production. We also observed that treatment with IL-10 signifi-
cantly inhibited the expression of TNF-a and IL-6 induced by
infection. Several factors contribute to chagasic cardiomyopathy
and tissue damage, including parasite persistence in heart tissue
[35]. The MMPs family may also contribute to the evolution of
chagasic cardiomyopathy, facilitating parasitic infection and tissue
Figure 4. IL-10 treatment inhibits pro-inflammatory cytokines and NOS2 expression and activity in T. cruzi infected cardiomyocytes.
(A) Cells were infected with T. cruzi or pre-treated with IL-10 (20 ng/ml) and TNF-a and IL-6 mRNA levels were analysed by Q-RT-PCR 4 h post
infection. (B) NOS2 expression was analysed by Wb in total protein extracts obtained after 48 h of T. cruzi infection or after pre-treatment with IL-10.
(C) Cells were grown on round glass cover slips and infected with T. cruzi or pre-treated with 20 ng/ml of IL-10 for 15 min. After 48 h of infection, NO
synthesis was detected in situ by the NO indicator DAF-FM and visualized by fluorescence microscopy. For A, results were normalized against 18S and
represent the mean6SD of three independent experiments. For B, results show the mean6SD (n = 4) and protein levels were normalized against a-
actin. In C, microphotographs (400X) are representative of three independent experiments performed. The graph represents the mean6SD of the
integrated fluorescence densities. **p,0.01 vs. control cells;ˆp,0.01 vs. T. cruzi infected cells; #p,0.05 vs. T. cruzi infected cells.
doi:10.1371/journal.pone.0079445.g004
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remodeling. Furthermore, increased activity of cardiac MMP-2
and MMP-9 has been associated with mortality during the acute
phase of T. cruzi infection, suggesting an important role in the
induction of chagasic acute myocarditis [36]. In previous works,
we have demonstrated that cardiomyocytes are able to express
MMPs after LPS challenge or T. cruzi infection in different
experimental models [3,4,23,37]. In the present work, we found
that pre-treatment with IL-10 inhibited MMP-2 and MMP-9
expression and activity after T. cruzi infection.
It has been described that the modulatory effect of IL-10 in the
inflammatory response is associated with the inhibition of the NF-
kB pathway [38–40]. Our results show that IL-10 treatment
promoted less degradation of cytosolic IkB-a and reduced the
translocation of p65 to the nucleus in infected cardiomyocytes
compared with the untreated cells. Given that T. cruzi infection
promotes ERK/MAPK activation, we also evaluated the role of
IL-10 in infected cardiomyocytes and observed a decrease in
phosphorylation levels of ERK1/2, indicating the inhibition of the
activity of this pathway.
This study also provides evidence that phosphorylation of
STAT3 contributes to the inflammatory response. In this regard, it
has been shown that treatment with IL-10 in a murine model of
myocardial infarction inhibits inflammatory parameters and
participates in the cardiac remodeling process via activation of
STAT3 [41]. Our results regarding the precedence of T. cruzi-
dependent mechanisms over cytokine effects in the activation of
STAT3 are in agreement with those of Stahl et al. [42] and Ponce
et al [16] who show early activation of STAT3 upon infection of
cardiomyocytes with T. cruzi trypomastigotes. While in the model
of Ponce et al. [16] the anti-apoptotic effect of cruzipain is also
responsible for IL-6 production, in our model the T. cruzi factor(s)
responsible for STAT3 activation prior to IL-6 production remain
to be elucidated.
It has been described that phosphorylated STAT3 is dimerized
and induces nucleus transcription of the SOCS-3 gene [43]. There
is some evidence for the participation of this protein in the
mechanism by which IL-10 modulates the inflammatory response
in several models. For example, SOCS-3 has been reported as a
key mediator in the inhibitory effects of IL-10 in macrophages
stimulated with LPS [44–46] and in an in vivo model of collagen-
induced arthritis [47]. Recently, it has been reported that SOCS-3
acts as an endogenous inhibitor of pathological angiogenesis in
mouse models of cancer and proliferative retinopathy [42].
Moreover, macrophages infected with M. tuberculosis show inhibi-
tion of NF-kB activation and induction of SOCS-3 expression as a
mechanism of bacterial evasion of the inflammatory response [20].
Furthermore, the availability of knockout mice for SOCS-2 has
revealed that this protein is an important regulator of the immune
response generated in a acute model of T. cruzi infection [21].
However, the relevance of SOCS-3 expression in the anti-
inflammatory effects exerted by IL-10 in T. cruzi infections
remains to be investigated. In this work, we report that T. cruzi and
IL-10 can up-regulate SOCS-3 expression through the activation
of STAT3. However, the results demonstrate that SOCS-3
expression was higher in cardiomyocytes treated with IL-10.
Indeed, STAT3 inhibition by stattic, a specific inhibitor of STAT3
activation, prevented SOCS-3 expression, confirming that SOCS-
3 is induced by IL-10/STAT3 in our model. To further evaluate
the mechanisms involved in IL-10 anti-inflammatory effects, we
investigated the consequences of the specific knock-down of
SOCS-3, demonstrating that SOCS-3 is essential for IL-10
signaling, since its silencing prevented IL-10 inhibitory effect on
the expression and activity of NOS2.
Regarding the use of exogenous IL-10 as a means of controlling
overt inflammatory responses, its advantages and drawbacks must
be taken under consideration. In an experimental model of
chronic enterocolitis in IL-10 KO mice, ip administration of IL-10
to weanlings significantly impeded the development of inflamma-
tion. While this treatment was not curative in adult mice, it
ameliorated the course of the disease reducing the overt
inflammatory Th1 response, characterized by exacerbated expres-
sion of IFN-c, TNF-a, IL-1b and NO, and the incidence of
colorectal denocarcinoma [48]. In a study on the beneficial effects
of IL-10 treatment in an experimental model of rheumatoid
arthritis, Persson et al [49] showed similar effects for IL-10: it
limited the development or reduced the ongoing effects of type II
collagen-induced arthritis. Regarding studies in humans, results
are more contradictory. In a study by van Roon et al. [50]
treatment of 6 patients with IL-10 didn’t improve their clinical
score. Also, Heo et al. [51] observed that, in patients with
rheumatoid arthritis, both peripheral blood and synovial fluid
Figure 5. Effect of IL-10 treatment on cardiac matrix metallo-
proteinase (MMP)-9 and MMP-2 expression and activity after T.
cruzi infection. (A) Neonatal cardiomyocytes were treated with IL-10
(20 ng/ml) for 15 min followed by 48 h of T. cruzi infection. MMP-9 and
MMP-2 mRNA levels were analysed by Q-RT-PCR. (B) Under the same
conditions as in A, zymograms of MMP-9 and MMP-2 activity were
carried out in culture media of neonatal cardiomyocytes after 72 h of T.
cruzi infection. White bars indicate the values of MMP-9 activity and
black bars indicate the values of MMP-2 activity. Peritoneal macro-
phages (Mps) were stimulated with LPS for 24 hours and used as a
positive control for MMP. In A, the results were normalized against 18S
and represent the mean6SD of three independent experiments. For B,
results represent the relative densitometric analysis of the activities of
Pro-MMP-9 and Pro-MMP-2 of four experiments performed. **p,0.01
vs. Control cells;ˆp,0.01, #p,0.05 vs. T. cruzi infected cells.
doi:10.1371/journal.pone.0079445.g005
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CD4+ T cells produced more IL-17 and less IL-10 than those of
healthy donors.
While treatment with IL-10 may be of significant aid in sterile
(pathogen-free) inflammatory disorders, its use in inflammatory
processes that arise from infections may represent a double edged
sword. For this reason, careful evaluation of the administration
route, dose and timing should be taken into consideration. Several
studies regarding the role of IL-10 in the progression of
experimental and human Chagas’ disease have been conducted.
Some of them have shown that IL-10 mediates susceptibility to
infection by T. cruzi. Reed et al. [52] showed that highly
susceptible mice transcribed IL-10 mRNA early upon infection
Figure 6. SOCS-3 is involved in the anti-inflammatory effects exerted by IL-10. Cardiomyocytes were pre-treated with 20 ng/ml of IL-10,
infected with T. cruzi or transfected with SOCS-3 siRNA for 72 h, pre-treated with IL-10 and infected for 48 h. (A) NOS2 expression levels were
determined by Wb. (B) In the same conditions NOS2 activity was evaluated by quantification of NO levels by Griess reaction in the culture media. (C)
and (D) TNF-a and IL-6 mRNA levels were analysed by Q-RT-PCR in the same conditions but only for 4 h post infection. (E) and (F) In the same
conditions as in (A), MMP-9 and MMP-2 mRNA levels were analysed by Q-RT-PCR. For A, results show the mean6SD (n = 3) and protein levels were
normalized against a-actin. In B, results are expressed as mean6SD (n = 3). In C,D,E and F, the results were normalized against 18S and represent the
mean6SD of three independent experiments **p,0.01 vs. control cells; #p,0.05 vs. T. cruzi infected cells; Qp,0.05 vs. T. cruzi infected+IL-10 treated
cells.
doi:10.1371/journal.pone.0079445.g006
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in contrast with those with less susceptibility. Moreover, anti-IL-10
treatment increased their survival.
Susceptibility to infection seems to be associated by the ability of
T. cruzi to drive dendritic cells (DC) towards a regulatory IL-10-
producing phenotype. Alba Soto et al. [53] showed that in IL-10
KO mice, DC are able to induce more potent Th1-type response
both in mixed-leukocyte reactions as well as upon T. cruzi lysate
stimulation of T cells in vitro, in comparison with wildtype mice.
Again, as shown by Reed et al. [52] their findings suggest that
early IL-10 production by infected mice contributes to T. cruzi
susceptibility. Altogether, these results suggest that treatment with
IL-10 during the acute stage of the disease might be disadvanta-
geous and even deleterious. In spite of this, IL-10 may exert
benefitial effects even during the acute stage of the disease. Guedes
et al. [54] have shown in a dog model of Chagas’ disease
evolution, that increased IL-10 expression during the acute
infection with three different parasite strains (Y, ABC and
Berenice-78) correlates positively with a better outcome during
the chronic stage in terms of development of chronic cardiomy-
opathy. In the same line of evidence, Roffeˆ et al. [55] using a
mouse model of T. cruzi infection with the Colombiana strain have
shown that IL-10 is required to avoid the inflammatory reaction
that leads to fatal myocarditis. In their model C57BL/6J (H-2b)
mice are resistant to fatal myocarditis in comparison with C3H/
HeSnJ (H-2k) mice. Deletion of IL-10 gene in mice with the
resistant background (H-2b) renders them susceptible to early
death, similarly to the genetically susceptible mice (H-2k).
The evidence regarding the role of IL-10 in the evolution of
human Chagas’ disease is less clear. This is mainly due to the fact
that detected acute cases are immediately treated using the
presently available trypanocidal drugs. Therefore, the data so far
available come from studies in chronically infected individuals at
the indeterminate or chronic stages of the disease. It has been
shown that the frequency of Treg cells is augmented in patients
with the indeterminate vs patients with the cardiac form of the
disease. In this regard, de Arau´jo et al. [56] showed that the
frequency of Treg (CD4+ CD25high Foxp3+) T cells that produce
IL-10 was higher in patients in the indeterminate phase than in
patients with the cardiac form of the disease. Interestingly, patients
with the higher frequency of IL-10-producing CD4+ CD25high
Foxp3+ also had the higher left ventricular ejection fraction, which
is a good prognosis marker. The same group [57], also recently
showed that patients with the indeterminate form of the disease
had higher frequencies of IL-10- and IL-17-expressing Treg than
patients with the cardiac form. Moreover, the latter had higher
frequencies of IL-6+, IFN-c+, TNF-a+ and CTLA-4+ Treg cells.
On the other hand, in a recent study by de Melo et al. [58] the
authors didn’t find any correlation between clinical stage and gene
expression of either IL-10 or IFN-c as measured by Q-RT-PCR,
upon stimulation of peripheral blood mononuclear cells with T.
cruzi recombinant antigens.
Altogether, the results coming from experimental models and
from research in patients, suggest that a delicate balance between
the pro- and anti-inflammatory responses during the acute
infection, is required to preclude either uncontrolled parasite
proliferation or the development of an overt inflammatory
response leading to tissue damage that, initiated during the acute
infection may result in chronic chagasic cardiomyopathy.
In summary, we show that IL-10 acts as a negative regulator of
pro-inflammatory signaling by up-regulation of SOCS-3 in
cardiomyocytes infected with T. cruzi. Our results provide new
insights into the probable mechanism by which IL-10/STAT3/
SOCS-3 negatively regulate NF-kB and ERK/MAPK–dependent
gene expression of pro-inflammatory mediators. Since cardiomy-
Figure 7. SOCS-3 silencing reverts IL-10-induced cardiomyocytes parasitism. Cells grown on glass coverslips were infected, infected and
treated with 20 ng/ml of IL-10 or silenced by siRNA for 72 h and then pre-treated with IL-10 and infected for 48 h. Infected cells were incubated with
rabbit polyclonal serum against to T. cruzi followed by FITC-labeled goat anti-rabbit IgG. Afterwards, cells were counterstained with DAPI (300 nM).
The percentage of infected cells (left bar graph) and the number of amastigotes/cell (right bar graph) are shown. Results represent the Mean6 SD of
two experiments. Microphotographs are representative of 30 fields taken at 400X magnification. White arrows show FITC-anti-T.cruzi-labelled
intracellular amastigotes.
doi:10.1371/journal.pone.0079445.g007
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ocytes are a major target of T. cruzi infection, producing significant
levels of NO and cytokines, the treatment with IL-10 using the
proper timing, dose and route might exert beneficial effects on the
heart, related to its anti-inflammatory effects in the acute phase of
Chagas’ disease that, as discussed earlier, may determine the fate
of an ongoing inflammatory response with, so far, unpredictable
consequences.
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